interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development
EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
Clinical Trials Information System (CTIS).
The EU Clinical Trials Register currently displays
44334
clinical trials with a EudraCT protocol, of which
7366
are clinical trials conducted with subjects less than 18 years old.
The register also displays information on
18700
older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see
Frequently Asked Questions ).
3 result(s) found for: Renal glomerulus.
Displaying page 1 of 1.
EudraCT Number: 2016-005141-23
Sponsor Protocol Number: 021FSGS16010
Start Date*: 2018-09-18
Sponsor Name:Retrophin, Inc.
Full Title: A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with...
Medical condition: Focal segmental glomerulosclerosis (FSGS)
Disease:
Version
SOC Term
Classification Code
Term
Level
21.1
10038359 - Renal and urinary disorders
10067757
Focal segmental glomerulosclerosis
PT
Population Age: Children, Adolescents, Under 18, Adults, Elderly
Gender: Male, Female
Trial protocol:GB(GB - no longer in EU/EEA)DE(Trial now transitioned)CZ(Trial now transitioned)FR(Trial now transitioned)ES(Ongoing)PL(Trial now transitioned)HU(Prematurely Ended)DK(Trial now transitioned)EE(Trial now transitioned)SE(Trial now transitioned)PT(Trial now transitioned)BE(Trial now transitioned)HR(Trial now transitioned)IT(Trial now transitioned)
Trial results:(No results available)
EudraCT Number: 2019-003607-35
Sponsor Protocol Number: C0221002
Start Date*: 2020-10-26
Sponsor Name:Pfizer Inc.
Full Title: PHASE 2, 24-WEEK, ADAPTIVE, OPEN LABEL, SEQUENTIAL COHORT TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06730512 FOLLOWING MULTIPLE DOSES IN ADULT SUBJECTS WITH FO...
Medical condition: Focal Segmental Glomerulosclerosis (FSGS)
Full Title: A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects with Selected Proteinuric Glomerular Diseases (E...
Medical condition: Proteinuric glomerular diseases including:
•Focal segmental glomerulosclerosis (FSGS)
•Minimal change disease (MCD)
•Immunoglobulin A nephropathy (IgAN)
•Immunoglobulin A vasculitis (IgAV)
•Al...
Disease:
Version
SOC Term
Classification Code
Term
Level
21.1
10038359 - Renal and urinary disorders
10067757
Focal segmental glomerulosclerosis
PT
20.0
10038359 - Renal and urinary disorders
10021263
IgA nephropathy
PT
22.1
100000004858
10082959
IgA vasculitis
LLT
20.0
10010331 - Congenital, familial and genetic disorders
10001843
Alport's syndrome
PT
21.1
10038359 - Renal and urinary disorders
10058326
Minimal change disease
LLT
Population Age: Infants and toddlers, Children, Adolescents, Under 18
Gender: Male, Female
Trial protocol:FR(Completed)ES(Temporarily Halted)SE(Trial now transitioned)PL(Temporarily Halted)DE(Restarted)IT(Trial now transitioned)NL(Trial now transitioned)
Trial results:(No results available)
Subscribe to this Search
To subscribe to the RSS feed for this search click
here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options:
Number of Trials to download:
Download Content:
Download Format:
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
• EEA CTAs: Date study was authorised to proceed • Outside EU/EEA: Date study was submitted in EudraCT